Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

th ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in approximately 130 patients with previously untreated metastatic pancreatic cancer. Plans for Rainier were announced in May 2013 and patient enrollment is expected to begin in mid-2013.
  • The Pacific™ Trial is an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in approximately 80 men with metastatic CRPC who are experiencing rising prostate-specific antigen (PSA) while receiving Zytiga® (abiraterone acetate). The trial was initiated in December 2012 and is currently enrolling at sites in the United States and Canada.
  • Second Quarter 2013 Financial Update and Results

  • Revenue for the three and six months ended June 30, 2013 increased to $6.3 million and $11.4 million, respectively. This compares to $2.4 million and $3.7 million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due to an increase in revenue earned through the Company's strategic collaboration with Teva, as a result of the clinical development activities associated with the AFFINITY trial that was initiated in August 2012.
  • Total operating expenses for the three and six months ended June 30, 2013 increased to $15.7 million and $29.1 million, respectively, compared to $8.4 million and $15.2 million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due primarily to increased clinical trial expenses associated with patient enrollment in the AFFINITY and Borealis-1 trials, higher costs directly associated with efforts to increase patient enrollment, increased employee expenses due to an increase in the number of employees to support our clinical development activities and increased toxicology and preclinical expenses related to apatorsen. These increases were partially off
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... CHAPEL HILL, N.C. , Aug. 29, 2014 /PRNewswire/ ... the face of regulatory and marketplace changes. CI leaders ... flounder. In a new Best Practices, ... a host of actionable insights, including: - ... and cheaper than primary research - Internal ...
    (Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
    (Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
    Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
    ... Owner Pleads Guilty; Dog Wardens Revoke,Snyder County Kennel ... officials are cracking down on unsatisfactory kennels with ... prosecutor and dog,wardens, Special Deputy Agriculture Secretary for ... dog wardens continue to make progress enforcing current,regulations. ...
    ... Corp.,(Nasdaq: GENZ ) announced today that the ... trial examining the safety and effectiveness of,Clolar(R) (clofarabine) ... leukemia (AML) who are unlikely to benefit from ... to provide substantial,evidence for expanding the current product ...
    Cached Medicine Technology:Dog Law Officers' Crackdown on Unsatisfactory Kennels Protecting Animals, Consumers 2Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 2Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 3Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 4Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 5Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 6
    (Date:8/30/2014)... Franklin, TN (PRWEB) August 30, 2014 ... techniques, including nine mobilizations and six muscle energy techniques. ... also narrates and demonstrates twenty-seven examination techniques for the ... course supports Dr. Reiman's live course presentation with ... Objectives, Applying a differential diagnosis ...
    (Date:8/30/2014)... Celebrating its 25th year, Recovery Month ... the fact that millions of Americans lives have ... addiction and mental health disorders. Every September ... programs and other community groups to recognize the ... The rallying theme for Substance Abuse and ...
    (Date:8/30/2014)... Barcelona, Spain Saturday 30 August 2014: The first ... They are presented at ESC Congress 2014 by Task ... Aboyans (France). , The "2014 ESC Guidelines on the ... online in European Heart Journal (1) ... "Previous ESC recommendations were published in 2001 but they ...
    (Date:8/29/2014)... Daily Gossip writes in its review that ... market nowadays. This method promises to teach readers how to ... some effective alternative sources for the production of energy. ... wind and solar power. , The Home Made Energy ... an eBook. So, this is an online guide that will ...
    (Date:8/29/2014)... MD (PRWEB) August 30, 2014 AGH ... by the Doctors in Delaware at Atlantic ... of free health-related services. In addition to no-cost blood ... Maryland offers first aid care at local sports tournaments. ... and other medical staff provide free disease management and ...
    Breaking Medicine News(10 mins):Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 3Health News:First comprehensive ESC Guidelines on aortic diseases published 2Health News:First comprehensive ESC Guidelines on aortic diseases published 3Health News:Home Made Energy Review Exposes Simple Method to Access Alternative Energy Sources 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
    ... New Jersey medical malpractice attorney David A. Mazie of Mazie Slater Katz ... history for a 47-year old man rendered legally blind as a result ... Russo. , ... Roseland, NJ (PRWEB) July 9, 2006 -- ...
    ... part of uKarma,s vertical integration strategy and will, ... complementary health and wellness brands, LOS ANGELES, ... a lifestyle multimedia and consumer products company,focused on ... Xflowsion studio will open in Southern California in ...
    ... Wrong on Veterans Health Care, WASHINGTON, July ... Employees (AFGE) launched a nationwide radio ad,campaign raising ... care. In addition to the radio ads, AFGE, ... launched a Web site, http://www.fundtheva.com, and a ...
    ... extended backorder from the manufacturer, Wedgewood Pharmacy will compound this ... suspension in the most frequently prescribed strengths. Acepromazine will be ... ... SWEDESBORO, N.J. (Business Wire EON) July ...
    ... Summer and ... Throughout the Year, PINELLAS PARK, Fla., July 9 ... its effects on the skin, many,are not aware that the eyes are ... and Transitions Optical found that nearly 80,percent of consumers report knowing that ...
    ... WASHINGTON, July 9 Updates on the impact ... MRSA infections,and the importance of childhood immunizations were ... Press Club in Washington, D.C. The news,conference, sponsored ... addressed the growing challenge of prevention and treatment ...
    Cached Medicine News:Health News:$2.1 Million Lasik Malpractice Settlement Against Celebrity Physician Dr. Joseph Dello Russo 2Health News:uKarma to Open First Xflowsion Fitness Studio With Celebrity Trainer Eric Paskel 2Health News:Union Representing VA Workers Launch Nationwide Radio Campaign, Web Site and Viral Videos for Full VA Funding 2Health News: Wedgewood Pharmacy Responds to Acepromazine Maleate Drug Shortage 2Health News:Study Confirms Americans Place Their Vision at Risk Year Round 2Health News:Study Confirms Americans Place Their Vision at Risk Year Round 3Health News:Public Health Experts Provide Update on Current Infectious Diseases Threats 2Health News:Public Health Experts Provide Update on Current Infectious Diseases Threats 3
    The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: